Countries China

FDA Clears CARsgen's CT071 for Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

 December 05, 2023 | News

China Pharma Completes Third-Party Testing for Dry Eye Therapeutic Device

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 34...

 November 30, 2023 | News

Merck Expands Newest Biologics Testing Center in Shanghai

Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million...

 November 30, 2023 | News

Everest Medicines Gets NMPA Approval for Nefecon® in China for IgA Nephropathy

--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patient...

 November 27, 2023 | News

DxVx Plans License-In of OVM-200, Launches Clinical Trials in Asia

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK- DxVx plans to proceed its own clinical trials in Asia, including Korea and Chi...

 November 27, 2023 | News

China Faces Surge in 'Undiagnosed Pneumonia' Cases Among Children

The outbreak initially surfaced in northern China, prompting the World Health Organization (WHO) to issue an "official request" to ...

 November 27, 2023 | News

Simcere and Connect ink exclusive deal for autoimmune drug Rademikibart.

Pursuant to the Agreement, Simcere obtains the exclusive rights in the development, manufacturing, and commercialization of Rademikibart for all indication...

 November 24, 2023 | News

BeiGene and Ensem Therapeutics Partner to Advance CDK2 Inhibitor

“We are committed to developing novel molecules with the potential to transform the therapeutic landscape for cancer patients, and this partnership f...

 November 23, 2023 | News

WuXi Biologics Achieves Breakthrough Productivity of ~6 g/L/day in Integrated Continuous Process at Pilot Scale

  By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture...

 November 23, 2023 | News

Innovent and AnHeart's Taletrectinib NDA Accepted by China's NMPA

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

 November 23, 2023 | News

XtalPi and EDDC Collaborate on Biomedical Innovation with Robotics and Language Models

Building upon an ongoing collaboration that was initiated in December 2022 to utilize artificial intelligence (AI) and automation to develop targ...

 November 22, 2023 | News

IASO Bio Sets Up Global CAR-T Center in China for Global MM Patients

On June 30, 2023, the China National Medical Products Administration (NMPA) approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCAS...

 November 22, 2023 | News

Porton Advanced and Ascle Therapeutics Form Strategic Partnership for NK Cell Applications in Cancer Prevention, Beauty, and Anti-aging

Porton Advanced is committed to providing end-to-end gene and cell therapy CDMO services, covering fields such as plasmids, cell therapy, gene therapy, and...

 November 21, 2023 | News

WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange

WuXi XDC issued a total of 178,446,000 shares under the global offering at an offer price of HK$20.60 per share (being the high-end of the indica...

 November 20, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close